News about Market

Vedana Therapeutics Launches with USD 46 Million Series A Financing for Migraine Therapies

Vedana Therapeutics has launched with USD 46 million in Series A financing to advance next-generation migraine therapies. Backed by migraine experts and investors, the company is developing innovative treatments targeting clinically validated pathways to help patients achieve lasting freedom from migraine.

Market | 17/06/2026 | By News Bureau |  145

Glenmark USA Launches Methylene Blue Injection USP 50 mg/10 mL

Glenmark Pharmaceuticals has launched Methylene Blue Injection USP 50 mg/10 mL, a bioequivalent and therapeutically equivalent generic version of ProvayBlue.

Market | 17/06/2026 | By News Bureau

AviadoBio Broadens vMiX Platform Agreement with King's College London

AviadoBio has expanded its exclusive vMiX Precision Gene Silencing Platform agreement with King’s College London to cover all human therapeutic areas. Backed by positive AVB-406 preclinical data, the RNAi-based platform highlights broad potential for targeted gene therapies.

Market | 17/06/2026 | By News Bureau |  110

Saptalis Launches Cyclosporine Ophthalmic Emulsion

Saptalis Pharmaceuticals has launched Cyclosporine Ophthalmic Emulsion 0.05 percent in 30- and 60-count single-use vials, expanding its ophthalmology portfolio and improving access to high-quality treatment options for patients.

Market | 16/06/2026 | By News Bureau

Dr. Reddy's Announces the First-to-Market Launch of Bosutinib Tablets 400 mg

Dr. Reddy’s has launched Bosutinib Tablets 400 mg in the US, becoming the first generic equivalent of Bosulif available in the market.

Market | 15/06/2026 | By News Bureau

Teva Completes Acquisition of Emalex Biosciences

Teva has completed its acquisition of Emalex Biosciences, strengthening its late-stage neuroscience pipeline. The deal supports Teva’s Pivot to Growth strategy.

Market | 12/06/2026 | By News Bureau |  168

GSK Enters Agreement to Acquire Nuvalent

GSK has agreed to acquire Nuvalent in a multi-product oncology deal that strengthens its lung cancer portfolio with two late-stage, potential best-in-class therapies—zidesamtinib and neladalkib—for non-small cell lung cancer.

Market | 10/06/2026 | By News Bureau |  264

Syntax Bio and Mayo Clinic Partner on Type 1 Diabetes Cell Therapy

Syntax Bio and Mayo Clinic have partnered to accelerate the development of stem cell-derived pancreatic cell therapies for Type 1 Diabetes (T1D). The collaboration aims to advance regenerative medicine approaches that could restore insulin-producing cells.

Market | 10/06/2026 | By News Bureau |  103

Wegovy Pill Prescriptions Surpass 3 Million as Novo Nordisk Presents New ADA 2026 Data

Novo Nordisk announced that Wegovy pill prescriptions have surpassed 3 million since launch, marking one of the largest US pharmaceutical launches by volume. Most prescriptions are from people new to GLP-1 therapy, expanding access to obesity treatment, while new clinical analyses are being presented at ADA 2026.

Market | 10/06/2026 | By News Bureau |  611

Incyte to Acquire Vega Therapeutics, Expanding Hematology Portfolio

Incyte has agreed to acquire Vega Therapeutics, expanding its hematology portfolio into bleeding disorders with the addition of VGA039, a phase 3 investigational monoclonal antibody for von Willebrand disease. The deal includes USD 1.25 billion upfront and up to USD 750 million in additional payments upon achievement of sales milestones.

Market | 09/06/2026 | By News Bureau |  114